Jenna, 38, describes herself as "a tired mom of two," but the years of fatigue, weight gain, and hair loss that came with her Hashimoto's hypothyroidism may finally be loosening their grip. After decades of managing an autoimmune disorder that kept her thyroid hormones perpetually out of balance, she enrolled in a landmark clinical trial at UConn Health in Connecticut—one that's now exploring whether adding a second synthetic thyroid hormone to standard treatment could give the roughly 10% of adults with hypothyroidism a real escape from the exhaustion that daily medication hasn't fully resolved.
When Jenna was diagnosed with Hashimoto's hypothyroidism in her 20s, she did what most patients do: she started taking levothyroxine, a synthetic version of T4, the primary thyroid hormone. It's the gold standard. Levothyroxine works well for many people, stabilizing metabolism and helping the body regulate everything from heart function to cholesterol. But for Jenna and countless others, the standard dose couldn't quite catch up with her body's fluctuating hormone needs. "It's trial and error until you find a sweet spot, and then it will fluctuate again," she explains. Monday's dose would feel right, but by Wednesday it might not be enough, and by the weekend it could be too much. The warning signs—crushing fatigue, hair loss, that bone-deep lethargy—often arrived too late, when her annual blood test revealed her thyroid-stimulating hormone, or TSH, had drifted out of range.
That frustration is precisely what brought Dr. Francesco Celi, endocrinologist and chair of UConn Health's Department of Medicine, to launch this National Institutes of Health-funded trial. The clinical paradox he confronts in his practice is stark: doctors excel at bringing TSH into the normal range, yet patients still report feeling unwell. The problem, Celi believes, lies in a hormone that standard treatment often overlooks—T3, or triiodothyronine, which the body naturally produces in smaller quantities than T4. Over two decades of research, his team has been testing whether adding liothyronine, a synthetic T3, to the standard levothyroxine regimen could close the gap between normal lab values and how patients actually feel.
The trial, which is the only one of its kind running in the United States, randomly assigns participants to one of three groups: those receiving levothyroxine plus placebo, those on levothyroxine plus a daily dose of liothyronine, and those taking levothyroxine plus liothyronine twice daily. Each participant is monitored closely for six months, with bloodwork and study visits every six weeks—far more frequent than the annual checks Jenna used to receive. The dosage adjusts at each visit based on lab results, and participants report their quality of life through questionnaires, giving researchers a clear picture of whether the addition of T3 actually translates to feeling better.
For Jenna, the intensive monitoring alone has been revelatory. "They're checking me every six weeks, where before I was getting checked every year," she says. "And it's incredibly safe and convenient." But if the trial confirms what preliminary evidence suggests—that T3 therapy reduces the lingering symptoms that levothyroxine alone can't fully address—the implications could reshape how millions of hypothyroid patients are treated. The hope is that Celi's findings will reach not just endocrinologists but primary care physicians everywhere, opening a door for those who've resigned themselves to managing a condition that, with the right combination of hormones, might finally feel manageable.